Cannabinoids and glaucoma

British Journal of Ophthalmology

Volumn 88, Issue 5, 2004, Pages 708-713

  Tomida, I ^b   Perlwee, R G ^c   Azuara Blanco, A ^a,b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ANANDAMIDE; ARACHIDONYL 2' CHLOROETHYLAMIDE; ARACHIDONYLCYCLOPROPYLAMIDE; CANNABIDIOL; CANNABIGEROL; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CYCLODEXTRIN; DEXANABINOL; DRONABINOL; L 759633; L 759656; METHANANDAMIDE; NABILONE; NOLADIN; O 1812; OLIGOSACCHARIDE; RIMONABANT; UNCLASSIFIED DRUG;

BLINDNESS; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MICROEMULSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

CANNABINOIDS; GLAUCOMA; HUMANS; OPHTHALMIC SOLUTIONS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 1942517916     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.032250     Document Type: Review

References (71)

1. Frankhauser M. Cannabis in der westlichen Welt. In: Grotenhermen F, ed. Cannabis und cannabinoide. 1st ed. Berlin: Verl Hans Huber, 2001:57-71.
2. Chalsma AL, Boyum D. Marijuana situation assesment. Washington DC: Office of National Drug Control Policy, 1994.
3. Schwab IR, Husted R, Liegner JT, et al. Complementary therapy assessment: Marijuana in the treatment of Glaucoma. San Francisco: American Academy of Ophthalmology, Complementary Therapy Task Force, 1999.
4. Grotenhermen F. Die Wirkungen von Cannabis und der Cannabinoide. In: Grotenhermen F, ed. Cannabis und cannabinoide, 1st ed. Berlin: Verl Hans Huber, 2001:75-86.
5. ElSohly MA. Chemical constituents of cannabis. In: Grotenhermen F, Russo E, eds. Cannabis and cannabinoids. Pharmacology, toxicology and therapeutic potential. New York: Haworth Press, 2002:27-36.
6. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999;6:635-64.
7. Pertwee RG. The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V, ed. Cannabinoids. New York: Landes Bioscience, 2003 (in press).
8. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202.
9. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-80.
10. Porcella A, Casellas P, Gessa GL, et al. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Mol Brain Res 1998;58:240-5.
11. Straiker A, Maguire C, Makie K, et al. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Visual Sci 1999;40:2442-8.
12. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002;66:101-21.
13. Piomelli D, Giuffrida A, Calignano A, et al. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000;21:218-24.
14. Pertwee RG. Inverse agonism at cannabinoid receptors. In: Esteve Foundation Symposium X. Inverse Agonism. Amsterdam: Elsevier, 2003 (in press).
15. Pertwee RG. Novel pharmacological targets for cannabinoids. Current Neuropharmacology 2003 (in press).
16. Hampson AJ, Grimaldi M, Axelrod J, et al. Cannabidiol and (-)D9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998;95:8268-73.
17. Hampson AJ, Grimaldi M, Lolic M, et al. Neuroprotective antioxidants from marijuana. In: Reactive oxygen species: from radiation to molecular biology. Ann NY Acad Sci 2000;899:274-82.
18. Pertwee RG. Neuropharmacology and therapeutic potential of cannabinoids. Addiction Biology 2000;5:37-46.
19. Barth F. Cannabinoid receptor agonists and antagonists. Expert Opinion On Therapeutic Patents 1998;8:301-13.
20. Pertwee RG. Cannabinoid receptor ligands: clinical and neuropharmacological considerations relevant to future drug discovery and development. Expert Opinion on Investigational Drugs 2000;9:1553-71.
21. Galve-Roperh I, Sánchez C, Cortés ML, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Med 2000;6:313-19.
22. Pertwee RG. Cannabinoid receptors and pain. Progress in Neurobiology 2001;63:569-611.
23. Pertwee RG. Cannabinoids. In: Bountra C, Munglani R, Schmidt WK, eds. Pain current understanding, emerging therapies and novel approaches to drug discovery. New York: Marcel Dekker, 2003:683-706.
24. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002;95:165-74.
25. Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 1993;7:389-91.
26. Müller-Vahl KR, Kolbe H, Schneider U, et al. Cannabis in movement disorders. Forschende Komplementärmedizin 1999;6(Suppl 3):23-7.
27. Müller-Vahl KR, Schneider U, Kolbe H, et al. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatr 1999;156:495.
28. Hepler RS, Frank IR. Marihuana smoking and intraocular pressure (letter). JAMA 1971;217:1392.
29. Brown B, Adams AJ, Haegerstrom-Portnoy G, et al. Pupil size after use of marijuana and alcohol. Am J Ophthalmol 1977;83:350-4.
30. Flom MC, Adams AJ, Jones RT. Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon? Invest Ophthalmol 1975;14:52-5.
31. Dawson WW, Jiménez-Antillon CF, Perez M, et al. Marijuana and vision -after ten years̀ use in Costa Rica. Invest Ophthalmol Visual Sci 1977;16:689-99.
32. Hashibe M, Ford DE, Zhang ZF. Marijuana smoking and head and neck cancer. J Clin Pharmacol 2002;42(Suppl):103-7.
33. Merritt JC, McKinnon S, Amstrong JR, et al. Oral delta 9-tetrahydrocannabinol in heterogeneous glaucomas. Ann Ophthalmol 1980;12:947-50.
34. Colasanti BK, Craig CR, Allora RD. Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Exp Eye Res 1984;39:251-9.
35. 9- tetrahydrocannabinol or cannabichromene. Exp Eye Res 1984;38:63-71.
36. Liu JHK, Dacus AC. Central nervous system and peripheral mechanisms in ocular hypotensive effect of cannabinoids. Arch Ophthalmol 1987;105:245-8.
37. 1 receptor antagonist SR 141716A on cannabinoids induced ocular hypotension in normotensive rabbits. Life Sci 1998;63:2181-8.
38. Song ZH, Slowey CA. Involvement of cannabinoids receptors in the intraocular pressure lowering effects of WIN-55,212-2. Pharmacol Exp Ther 2000;292:136-9.
39. Chien FY, Wang RF, Mittag TW, et al. Effect of WIN-55,212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch Ophthalmol 2003;121:87-90.
40. Korzyn AD. The ocular effects of cannabinoids. Gen Pharmac 1980;101:591-3.
41. McDonald TF, Cheeks L, Slagle T, et al. Marijuana-derived material induced changes in monkey ciliary processes differ from those in rabbit ciliary processes. Curr Eye Res 1991;4:305-12.
42. 9-tetrahydrocannabinol on aqueous dynamics and ciliary body permeability in the rabbit. Exp Eye Res 1973;15:499-507.
43. Sugrue MF. New approaches to antiglaucoma therapy. J Med Chem 1997;40:2793-809.
44. 9-tetrahydrocannabinol. Invest Ophthalmol Vit Sci 1974;13:422-9.
45. 9- tetrahydrocannabinol and indometacin. Ophthalmic Res 2001;33:217-20.
46. Pate DW, Järvinen K, Urtti A, et al. Effects of topical anandamides on intraocular pressure in normotensive rabbits. Life Sci 1996;58:1849-60.
47. Pate DW, Jarvinen K, Urtti A, et al. Effects of topical alpha-substituted anandamides on intraocular pressure in normotensive rabbits. Pharm Res 1997;14:1738-43.
48. 2-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits. Life Sci 2003;72:837-42.
49. Järvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacology and Therapeutics 2002;95:203-220.
50. Green K, Roth M. Ocular effects of topical administration of delta-9-tetrahydrocannabinol in man. Arch Ophthalmol 1982;100:263-265.
51. Jay WM, Green K. Multiple drop study of topically applied 1% delta-9-tetrahydrocannabinol in human eyes. Arch Ophthalmol 1983;101:591-3.
52. Jarho P, Urtti A, Pate DW, et al. Increase in aqueous solubility, stability and in vivo corneal permeability of anandamide by hydroxyprapyl- β-cyclodextrin. Int J Pharm 1996;137:209-17.
53. 9-tetrahydrocannabinol. Life Sci 1998;63:381-4.
54. 9- tetrahydrocannabinol. Curr Eye Res 2000;29:496-501.
55. 9- tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. Curr Eye Res 2000;21:566-70.
56. Porcella A, Maxia Ch, Gessa GL, et al. The synthetic cannabinoids WIN-55,212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur J Neurosci 2001;13:409-12.
57. Laine K, Järvinen K, Mechoulam R, et al. Comparison of the enzymatic stability and intraocular pressure effects of 2-Arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci 2002;43:3216-22.
58. Naveh N, Weissman C, Muchtar S, et al. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefes Arch Clin Exp Ophthalmol 2000;238:334-8.
59. Levin LA. Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Surv Ophthalmol 1999;43(Suppl):98-101.
60. Shen M, Thayer SA. Cannabibinoid receptor agonists protect cultured rat hipocampal neurons from exitotoxicity. Mol Pharmacol 1998;54:459-62.
61. Mechoulam R, Panikashivili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002;8:58-61.
62. 1 cannabinoid receptor induction in experimental stroke. Ann Neurol 2000;48:257-261.
63. Yoles E, Belkin M, Schwartz M. HU-211, a nonpsychotropic cannabinoid, produces short-and long-term neuroprotection after optic nerve axotomy. J Neurotrauma 1996;13:49-57.
64. 1. J Neurochem 2002;80:448-56.
65. Gray GA, Battistini B, Webb DJ. Endothelins are potent vasoconstrictors, and much more besides. Trends Pharmacol Sci 2000;21:38-40.
66. Haeffliger IO, Meyer P, Flammer J, et al. The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology? Surv Ophthalmol 1994;39:123-32.
67. Nicolela MT, Ferrier SN, Morrison CA, et al. Effects of cold-induced vasospasm in glaucoma. The role of endothelin-1. Invest Ophthalmol Vis Sci 2003;44:2565-72.
68. Age-Related Eye Disease Study Research Group. A randomised, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 2001;119:1417-36.
69. Casanova ML, Blázques C, Martinez-Palacio J, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoids receptors. J Clin Inverst 2003;111:43-50.
70. The Eye Tech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-52.
71. Zurier RB. Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 2003;88:462-6.